Business Description
AN2 Therapeutics Inc
NAICS : 325412
SIC : 2834
1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027
Description
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -0.73 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 96.5 | |||||
| 9-Day RSI | 91.49 | |||||
| 14-Day RSI | 84.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.7 | |||||
| Quick Ratio | 17.7 | |||||
| Cash Ratio | 17.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -61.95 | |||||
| ROIC % | -655.45 | |||||
| ROCE % | -66.69 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -11.95 | |||||
| EV-to-EBITDA | -11.95 | |||||
| EV-to-FCF | -12.58 | |||||
| Earnings Yield (Greenblatt) % | -8.37 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:ANTX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -1.53 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 84.75 | ||
| 14-Day ATR ($) | 1.826636 | ||
| 20-Day SMA ($) | 9.616 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 6.8789 - 23.58 | ||
| Shares Outstanding (Mil) | 19.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AN2 Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||